ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com. Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors ...

Group 1 - EyePoint Pharmaceuticals reported a quarterly loss of $0.65 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.55 per share a year ago [1] - The company posted revenues of $24.45 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 345.17%, and up from $11.68 million year-over-year [2] - The stock has underperformed, losing about 16.1% since the beginning of the year, while the S&P 500 declined by 4.7% [3] Group 2 - The earnings outlook for EyePoint Pharmaceuticals is mixed, with the current consensus EPS estimate for the coming quarter at -$0.67 on revenues of $5.49 million, and -$2.84 on revenues of $13.96 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which EyePoint Pharmaceuticals belongs, is currently in the top 35% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for EyePoint Pharmaceuticals is currently reflected in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Halozyme Therapeutics, Inc. First Quarter Financial & Operating Results NASDAQ: HALO May 6, 2025 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2025 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such guidan ...

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative solutions [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [3] - Halozyme has impacted over one million patients through its technology, which is used in ten commercialized products across more than 100 global markets [3] Product Development - Halozyme develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies to enhance convenience, reliability, and patient comfort [4] - The company has two proprietary commercial products: Hylenex® and XYOSTED®, along with partnered products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Financial Results - Halozyme will release its first quarter 2025 financial and operating results on May 6, 2025, after the market closes [1] - A conference call to discuss these results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, with live access available through pre-registration [1][2]

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous inje ...